Ecolab (ECL) faces "less potential for outsized stock gains" with prospects for risks and reward "balanced at current levels," UBS Securities said Monday in a report.
After 22% earnings per share growth annually in the past two years, adjusted EPS is expected to return to a "normal" range of 12% to 15%, the report said.
UBS downgraded Ecolab's stock to hold from buy with a 12-month price target of $276.
Following Q3 results, UBS trimmed 2025-26 EPS forecasts about 4% with margins and beats below expectations and pricing and costs benefits "now largely done," according to the report.
Institutional segment organic growth is expected to moderate from the current high single-digit percentage level, countered by improving growth in industrial and health care and life sciences, UBS said.
Ecolab shares fell 0.7% in recent trading Monday.
Price: 242.79, Change: -1.79, Percent Change: -0.73
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。